Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

BACKGROUND: Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction of individual response to treatment remains an unsolved clinical problem. Particularly, administration of an inefficient chemotherapeutic regimen should be avoided. Therefore, a better understand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Michlmayr, A, Bachleitner-Hofmann, T, Baumann, S, Marchetti-Deschmann, M, Rech-Weichselbraun, I, Burghuber, C, Pluschnig, U, Bartsch, R, Graf, A, Greil, R, Allmaier, G, Steger, G, Gnant, M, Bergmann, M, Oehler, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2967072/
https://ncbi.nlm.nih.gov/pubmed/20877360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605909
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados